Clinical Trial: Real-Life Clinical Efficacy of Acolamidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07306949) titled 'Real-Life Clinical Efficacy of Acolamidis in Participants With ATTR-CM and Association With Cardiac Biomarkers' on Dec. 15.

Brief Summary: The purpose of this study is to confirm that the treatment with acolamidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Transthyretin-type Cardiac Amyloidosis

Intervention: DRUG: Acolamidis

Participants will receive acolamidis tablets orally.

Recruitment Status: RECRUITING

Sponsor: Alexion Pharmaceuticals, Inc.

Disclaimer: Curated by...